Literature DB >> 27009928

The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up.

M J Kemna1,2, W Schlumberger3, P van Paassen1,2, C Dähnrich3, J G M C Damoiseaux4, J W Cohen Tervaert2.   

Abstract

The objective of this study is to investigate whether the avidity of proteinase-3-anti-neutrophil cytoplasmic antibody (PR3-ANCA) changes during follow-up in different subgroups of patients with granulomatosis with polyangiitis (GPA). We selected 10 patients with renal relapsing GPA, 10 patients with renal non-relapsing GPA and 10 patients with non-renal relapsing GPA. In all patients, an ANCA rise occurred during remission. The avidity was measured using a chaotropic approach at the time of an ANCA rise and at the time of a relapse in relapsing patients or time-matched during remission in non-relapsing patients. No difference was observed in the avidity at the ANCA rise between renal relapsing patients [26·2% (15·5-47·5)], renal patients without a relapse [39·6% (21·2-63·4)] and non-renal relapsing patients [34·2% (21·6-59·5)]. In renal relapsing patients, the avidity increased significantly from the moment of the ANCA rise to the relapse [difference 6·4% (0·0-17·1), P = 0·0273]. The avidity did not increase after an ANCA rise in renal non-relapsing patients [difference 3·5 (-6·0 to 10·1), P = 0·6250] or in non-renal relapsing patients [difference -3·1% (-8·0 to 5·0), P = 0·5703]. The avidity of PR3-ANCA increases after an ANCA rise during follow-up in renal relapsing patients, but not after an ANCA rise in renal patients who remain in remission or in non-renal relapsing patients.
© 2016 British Society for Immunology.

Entities:  

Keywords:  ANCA-associated vasculitis; PR3-ANCA; avidity; follow-up; granulomatosis with polyangiitis; proteinase 3; relapse; relative avidity index

Mesh:

Substances:

Year:  2016        PMID: 27009928      PMCID: PMC4955002          DOI: 10.1111/cei.12796

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

2.  Improvement of cytomegalovirus avidity testing by adjusting the concentration of CMV-specific IgG in test samples.

Authors:  Volker Dangel; Ursula Bäder; Gisela Enders
Journal:  J Clin Virol       Date:  2005-11-18       Impact factor: 3.168

3.  Important parameters for evaluation of antibody avidity by immunosorbent assay.

Authors:  Jordan D Dimitrov; Sebastien Lacroix-Desmazes; Srinivas V Kaveri
Journal:  Anal Biochem       Date:  2011-07-26       Impact factor: 3.365

4.  Influence of myeloperoxidase by anti-myeloperoxidase antibodies and its association with the disease activity in microscopic polyangiitis.

Authors:  Peng-Cheng Xu; Min Chen; Zhao Cui; Ming-Hui Zhao
Journal:  Rheumatology (Oxford)       Date:  2010-07-31       Impact factor: 7.580

5.  Analytical issues possibly affecting the performance of commercial human cytomegalovirus IgG avidity assays.

Authors:  M Berth; L Grangeot-Keros; F Heskia; J-M Dugua; C Vauloup-Fellous
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-30       Impact factor: 3.267

6.  Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis.

Authors:  M Yoshida; M Sasaki; I Nakabayashi; M Akashi; T Tomiyasu; N Yoshikawa; T Kojima; N Ohno; M Yamada
Journal:  Clin Exp Rheumatol       Date:  2009 Jan-Feb       Impact factor: 4.473

Review 7.  Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy.

Authors:  Harry E Prince; Mary Lapé-Nixon
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

8.  Estimating renal survival using the ANCA-associated GN classification.

Authors:  Marc Hilhorst; Benjamin Wilde; Peter van Breda Vriesman; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

9.  A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  J Damoiseaux; C Dähnrich; A Rosemann; C Probst; L Komorowski; C A Stegeman; K Egerer; F Hiepe; P van Paassen; W Stöcker; W Schlumberger; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2008-03-28       Impact factor: 19.103

10.  Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis.

Authors:  Wei Lin; Min Chen; Ming-Hui Zhao
Journal:  Autoimmunity       Date:  2009-03       Impact factor: 2.815

View more
  6 in total

Review 1.  Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis.

Authors:  Mohammed S Osman; Jan Willem Cohen Tervaert
Journal:  Curr Rheumatol Rep       Date:  2019-12-26       Impact factor: 4.592

Review 2.  Biomarkers in connective tissue diseases.

Authors:  Neelakshi R Jog; Judith A James
Journal:  J Allergy Clin Immunol       Date:  2017-12       Impact factor: 10.793

3.  Do Relapses Follow ANCA Rises? A Systematic Review and Meta-Analysis on the Value of Serial ANCA Level Evaluation.

Authors:  Aram Al-Soudi; Yosta Vegting; Paul L Klarenbeek; Marc L Hilhorst
Journal:  Front Med (Lausanne)       Date:  2022-07-04

4.  Level and avidity of antineutrophil cytoplasmic antibodies specific to lactoferrin are useful biomarkers in systemic lupus erythematosus.

Authors:  Mirjana Gajic-Veljic; Branislav Lekic; Milos Nikolic; Jovan Lalosevic; Biljana Stojimirovic; Branka Bonaci-Nikolic
Journal:  Clin Rheumatol       Date:  2021-10-07       Impact factor: 3.650

5.  Red Blood Cell Distribution Width Can Predict Vasculitis Activity and Poor Prognosis in Granulomatosis with Polyangiitis.

Authors:  Ho Jae Kim; Juyoung Yoo; Seung Min Jung; Jason Jungsik Song; Yong Beom Park; Sang Won Lee
Journal:  Yonsei Med J       Date:  2018-03       Impact factor: 2.759

Review 6.  Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.

Authors:  Jérôme Granel; Brice Korkmaz; Dalila Nouar; Stefanie A I Weiss; Dieter E Jenne; Roxane Lemoine; Cyrille Hoarau
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.